Innovative Contracting

What are innovative contracts?

Changes in the payer landscape are accelerating while pressure on prices continues to increase. These developments are mainly driven by the availability of more data to payers, competitive pressure and increasingly demanding HTA (Health Technology Assessment) agencies.
demanding agencies.

Innovative contracts refer to the use of non-traditional contracts (financial or performance-based models) to overcome access problems that cannot be solved by traditional pricing offers and ensure patient access to medicines.

The aim is to find the simplest solution that meets the payer’s needs while achieving the pricing and patient access ambitions.

Innovative contracts offer pharmaceutical companies the opportunity to link clinical outcomes to pricing agreements, highlighting the medio-economic performance of the innovation.

In short, outcome-based (performance-based) contracting is a contract that includes a penalty or reward based on the observed performance of the product.

At Access Focus, we are developing and adopting new and innovative methods, including new financial models, based on performance and outcomes, to ensure patient access to medicines.

By implementing the innovative contracting strategy, we can help maximize the value of the company’s product portfolio and create more space for dialogue about drug performance for patients.

< p>The Access Focus team will support you in the development of the innovative contracting strategy as well as its execution.</p >

In addition to supporting individual contract opportunities, the team works to develop relevant tools and models, including financial assessments and assessment of risks for pharmaceutical companies. These tools allow Market Access teams to identify and evaluate local innovative contract opportunities to ultimately obtain and expand access to innovative products.


Health economics

The economic dimension has become of major interest to all players in the health system and is playing an increasingly important role in the evaluation of innovative strategies. It involves the use of complementary methodologies and various models. The integration of real-life patient experience data must now be considered in efficiency models.

Access Focus’ expert HEOR consultants have recognised experience in the economic evaluation of innovative health strategies (drugs, medical devices, vaccines, diagnostic or therapeutic interventions, e-health devices, new pathways, etc.).

Our services cover all innovative health strategies: drugs, medical devices, vaccines, diagnostic or therapeutic interventions, e-health devices, new pathways, etc.

Beyond economic analysis, our services focus on the evaluation of health outcomes as a whole.

Our services are aimed at multiple health stakeholders:
hospitals, manufacturers, start-ups, institutions and associations.


Medico-economic analyses

Medico-economic data can play a key role in raising awareness of a condition, making the case for a therapeutic area and justifying the value and reliability of your therapeutic solution.

In general, the most compelling uses of economic data combine both quantitative evidence (raw numbers and statistics from research, reports and surveys) and qualitative evidence (e.g. patient testimonials).

For example, some economic models have shown that investing in prevention, early detection, and better control and management is a very cost-effective way to improve public health that benefits both society and the economy. If not, it could lead to life-threatening complications, increase health-care costs related to complications, and undermine the ability of people with the disease to contribute to the economy.

However, economic data alone is not enough. Indeed, their usefulness is determined by the credibility of the source and how the data is interpreted and reported. This is why it is desirable to include references in your communications, during your meetings and dialogues with key stakeholders, the media or within the framework of your written documentation . Health economics analyzes are used in the context of price submissions intended for registration and/or reimbursement, with the aim of obtaining, maintaining or expanding Market Access. In addition, these medico-economic analyzes are often presented at national and international conferences or published in scientific journals aimed at a wider audience.

We offer a wide range of services


Medico-economic studies

  • E ciency studies: cost-effectiveness studies,
    cost-utility studies, cost-benefit studies
  • Modeling: Design, development and adaptation of efficiency models (decision trees, Markov models, discrete event simulation, micro simulations, dynamic models, …)
  • Budget Impact Model
  • Epidemiological models


Cost studies

  • Collection of data on costs and resources consumed in the Algerian context
  • Burden of illness (costs and cost drivers)


Patient-centred research

  • Quality of life studies: observational study, summary review
  • Quality of care perceived by the patient:
    questionnaire creation, validation, multi-channel collection, measurement
  • Study revealing patient preferences


Synthesis of evidence

  • Review of the literature: synthetic review, systematic review of the literature
  • Statistical analysis methods: meta-analyses, indirect comparisons


Strategic support

  • Health Technology Assessment: multidisciplinary assessment dealing with medical, economic, social, ethical, regulatory or organizational issues relating to the development, distribution and use of health technologies
  • Organization of expert committees and scientific committees



  • Writing scientific articles
  • Production of abstracts and scientific posters for communication at congresses
  • Provision of training and education

We listen to you

The Access Focus team is at your disposal to answer all your questions and queries. Do not hesitate to contact us.